Hepatotoxicity of antiretroviral drugs

Current Pharmaceutical Design

Volumn 11, Issue 28, 2005, Pages 3697-3710

  Abrescia, N ^b   D'Abbraccio, M ^a   Figoni, M ^a   Busto, A ^a   Maddaloni, A ^a   De Marco, M ^a  

^a AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^b A O D Cotugno   (Italy)

Author keywords

Aids; Antiretroviral drugs; Antiretroviral drugs hepatotoxicity; HAART; HAART hepatotoxicity; HIV; Management of antiretroviral drugs hepatotoxicity; Management of HAART hepatotoxicity

Indexed keywords

ABACAVIR; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; CYTOCHROME P450 3A; DELAVIRDINE; DIDANOSINE; DNA DIRECTED DNA POLYMERASE GAMMA; EFAVIRENZ; EMTRICITABINE; ISONIAZID; LACTIC ACID; LAMIVUDINE; METFORMIN; MITOCHONDRIAL DNA; NEVIRAPINE; PARACETAMOL; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; VIRUS DNA; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANTIVIRAL ACTIVITY; ARTHRALGIA; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATTY LIVER; HEADACHE; HEMODIALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLACTATEMIA; HYPOTENSION; INFECTION RISK; JAUNDICE; LACTIC ACIDOSIS; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER FAILURE; LIVER METABOLISM; LIVER NECROSIS; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; MYALGIA; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEVENS JOHNSON SYNDROME; SUPERINFECTION; TERATOGENICITY; VALIDATION PROCESS; VIRUS REPLICATION; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEPATITIS, TOXIC; HUMANS; LIVER; RISK FACTORS;

EID: 27744490956     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774580804     Document Type: Review

References (139)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Out-patient Study Investigators. N Engl J Med 1998; 338: 853-60.
2. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-87.
3. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24: 211-17.
4. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M. Mortality due to chronic viral liver disease among patients infected with immunodeficiency virus. Clin Infect Dis 2001; 33: 1793-95.
5. Lebovics E, Thung SN, Schaffner F, Radensky PW. The liver in the acquired immunodeficiency syndrome; a clinical and histologic study. Hepatology 1985; 5: 293-98.
6. Kahn SA, Saltzman BR, Klein RS, Mahadevia PS, Friedland GH. Hepatic disorders in the acquired immunodeficiency syndrome: a clinical and pathological study. Am J Gastroenterol 1986; 81: 1145-48.
7. Lefkowitch JH. The liver in AIDS. Semin Liver Dis 1997; 17: 335-44.
8. Ogedegbe AO, Sulkowski MS. Antiretroviral-associated liver injury. Clin Liver Dis 2003; 7: 475-99.
9. Schneiderman DJ, Arenson DM, Cello JP, Margaretten W, Weber TE. Hepatic disease in patients with acquired immunodeficiency syndrome (AIDS). Hepatology 1987; 7: 925-30.
10. Kelly JW, Dooley DP, Lattuada CP, Smith CE. A severe unusual reaction to trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus. Clin Infect Dis 1992; 14: 1034-39.
11. Melamed AJ, Muller RJ, Gold JW, Campbell SW, Kleinberg ML, Armostrong D. Possible zidovudine-induced hepatotoxicity. JAMA 1987; 16;258:2063.
12. Dubin G, Braffman MN. Zidovudine-induced hepatotoxicity. Ann Inter Med 1989; 110: 85-6.
13. Lai KK, Gang D, Zawacki J, Cooley T. Fulminant hepatic failure associated with 2′, 3′-dideoxyinosine. Ann Inter Med 1991; 115: 283-84.
14. Barbaro G, Di Lorenzo G, Asti A, Ribersani M, Belloni G, Grisorio B, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. Am J Gastroenterol 1999; 94: 2198-205.
15. Braun N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997; 349: 924-25.
16. Arribas JR, Ibanez C, Ruiz-Antoran B, Pena JM, Esteban-Calvo C, Frias J, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS 1998; 12: 1722-24.
17. Rodriguez-Rosado R, Garcìa-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998;12:1256.
18. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence for severe hepatotoxicity and risk factors associated with antiretro-viral combination therapy. J Infect Dis 2002; 186: 23-31.
19. Sulkowski MS, Thomas DI, Metha SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C or B virus infection. Hepatology 2002; 35: 182-89.
20. Orenstein R, Tsogas N. Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection. Pharmacother 2002, 22: 1468-78.
21. Saves M, Vandentorren S, Daucourt V, Marimoutou C, Dupon M, Couzigou P, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort; France 1996-98. AIDS 1999; 13: F115-21.
22. Martinez E, Blanco JL, Amaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-68.
23. Aceti A, Pasquazzi C, Zechini B, De Bac C and the LIVERHAART Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29: 41-48.
24. Lalezari JP. Clinical safety and efficacy of enfuvirtide (T-20), a new fusion inhibitor. A review of the presentation at the satellite symposium "LNew hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002. AIDS Read. 2003 Mar;13(S3): S9-13
25. Orenstein R, Le Gall SE. HIV treatment -associated hepatitis. The AIDS Read 1999; 9: 339-46.
26. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003; 22: 173-181.
27. Abrescia N, D'Abbraccio M, Figoni M, Busto A, Butrico E, De Marco M, et al. Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment-naïve female AIDS patient without hepatitis virus co-infection. J Antimicrob Chemother 2002; 50: 763-65.
28. Boxwell D, Haverkosh H, Kukich S, Struble K. Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after exposures. Worldwide, 1997-2000. MMVrR Morb Mortal Wkly Rep. 2001; 49: 1153-56.
29. Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV seropositive patients. AIDS 1993; 7:379-85.
30. Falco V, Rodriguez D, Ribera E, Martinez E, Miro JM, Domingo P, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002; 34: 838-46.
31. Spengler U, Lichterfeld M, Rockstroth JK. Antiretroviral drug-toxicity-a challenge for the hepatologist? J Hepatol 2002; 36: 283-94.
32. Miwa LJ, Jones JK, Pathiyal A, Hatoum H. Value of epidemiologic studies in determining the true incidence of adverse events. The non steroidal anti-inflammatory drug story. Arch Intern Med 1997; 157: 2129-36.
33. Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 2003; 23: 183-93.
34. Styrt BA, Piazza-Hepp TD, Chikami GK. Clinical toxicity of antiretroviral nucleoside analogs. Antiviral Res 1996; 31: 121-35.
35. Larrey D. Epidemiologic and individual susceptibility to adverse drug reaction affecting the liver. Semin Liver Dis 2002, 22: 145-55.
36. AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experiences. Rockville Md, Division of AIDS. National Institute of Allergy and Infectious Diseases; 1996.
37. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
38. Cooper CI, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002; 34: 1259-63.
39. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998; 12: 116-17.
40. Sanne I. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. AIDS 2000; 14 (S4): S12.
41. Saves M, Raffi F, Clevenbergh P, Marchou B, Waldner-Combernoux A, Morlat P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother 2000; 44: 3451-55.
42. den Brinker M, Wit FWNM, Wertheim-van Dillon PME, Jurriaans S, Weel J, van Leenwen R. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 2895-902.
43. Monforte d'Arminio A, Bugarini R, Pezzotti P, De Luca A, Antinori A, Mussini C, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection i HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001; 28: 114-23.
44. Greub G, Lederberger B, Bottegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV cohort study. Lancet 2000; 356: 1800-05.
45. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163 (18): 2187-95.
46. Lewis W, Dalakas MC. Mitochondrial toxicity of antiretroviral drugs. Nat Med 1995; 1: 1417-422.
47. Charton-Bain MC, Flamant M, Aubertin JM, Belair MF, Gilquin J, Kazatchkine M, et al. Lactic acidosis and hepatic mitochondrial changes during a treatment with zidovudine. Gastroenteroll Clin Biol 1997; 21: 979-81.
48. Moyle G. Hyperlactatemia and lactic acidosis: should routine screening be considered? AIDS Read 2002; 12: 344-48.
49. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717-23.
50. Boyle BA, Mitruka K. In: Ronald Baker Ed, Toxicities & Side effects. Guide to management of Nucleoside Analogue (NA). 2003; 4-25. Available on web site www.HIVandHepatitis.com
51. Ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J SID AIDS 2000; 11: 611-16.
52. Nuñez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 426-31.
53. Bonfanti P, Landonio S, Ricci E, Martinelli C, Fortuna P, Faggion I, et al. and the CISAI Study Group, Risk fitaors for hepatotoxicity in patients treated with highly active antiretroviral therapy, J Acquir Immune Defic Syndr 2001; 27: 316-18.
54. Olano JP, Borucki MJ, Wen JW, Haque AK. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis 1995; 21: 973-76.
55. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995; 90: 1433-36.
56. Montessori V, Harris M, Montaner JSG. Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin Liver Dis 2003; 23: 167-171.
57. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28: 1032-35.
58. Benhamou Y, Tubiana R, Thibault V. Tenofavir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Eng J Med 2003; 348: 177-178.
59. Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthwes G, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003; 17: F7-10.
60. Pillay D, Cane PA, Ratcliffe D, Atkins M, Cooper D. Evolution of lamivudine-resistant hepatitis virus and HIV-1 in coinfected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee. AIDS 2000; 14: 1111-16.
61. Wassef M, Keiser P. Hypersensitivity to zidovudine: report of a case and review of the literature. Am J Med 1992; 36:283-94.
62. Moyle G. Toxicity of antiretroviral nucleoside and non-nucleoside analogues. Is mitochondrial toxicity the only mechanism? Drug Saf 2000; 23: 467-81.
63. Emtriva product Labelling. Gilead Sciences, 2003.
64. Murphy MD, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tonofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003; 36: 1082-85.
65. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002; 78: 58-9
66. Bristol Myers Squibb company health care provider important drug warning letter. Jan 5, 2001.
67. Hill JB, Sheffield J, Zeeman GG, Wendel GD Jr. Hepatotoxicity with antiretroviral treatment of pregnant women. Obstetrics and Gynecology 200 1; 98: 909-11.
68. Ibdah JA, Bennett MJ, Rinaldo P, Zhao Y, Gibson B, Sims HF, et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999 3; 340: 1723-31.
69. Lafeullade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HCV/HIV co-infection. Lancet 2001; 357: 280-81.
70. Guyader D, Poinsignon Y, Cono Y, Saout L. Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C. J Hepatol 2002; 37: 289-91.
71. Salmon-Ceron D, Chanvelot-Moachon L, Abad S, Silberman B, Sogni P. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357:1803-04.
72. John Hopkins Hospital AIDS service. Available at: Website http//www.hopkins-aids.edu. Accessed Oct 2002.
73. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner JSG, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15: 1517-26.
74. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251-60.
75. Warren J, Boxwell DE, Kim NY, Drolet BA. Nevirapine associated Stevens-Johnson syndrome. Lancet 1998; 351: 567.
76. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296: 1439-43.
77. John M, Flexman J, French MAH. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998; 12: 2289-93.
78. Manegold C, Hannoun C, Wywiol A, Dietrich M, Polywska S, Chiwakata CB, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001; 32: 144-48.
79. Melvin DC, Lee JK, Belsey E, Arnold J, Murphy RL. The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS 2000; 14: 463-65.
80. Palmon R, Koo BC, Shoultz DA, Dieterich DT. Lack of hepatotoxicity associated with non-nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002; 29: 340-45.
81. Cattelan AM, Erne E, Salatino A, Trevenzoli M, Carretta G, Meneghetti F, et al. Severe hepatic failure related to nevirapine treatment. Clin Infect Dis 1999; 29: 455-56.
82. Center for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures-worldwide, 1997-2000. MMWR Moth MORT Wkly Rep 2001; 49: 1153-54.
83. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288: 222-35.
84. Bersoff-Matcha SJ, Miller WC, Aberg JA, van Der Horst C, Harmrich Jr HJ, Powderly WG, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32: 124-29.
85. Clarke S, Harrington P, Condon C, Kelleher D, Smith OP, Mulcahy F. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. Int J STD AIDS 2000; 11: 336-37.
86. Gonzales de Requeña D, Nuñez M, Jimenez Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002; 16: 290-91.
87. Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results firom a national multicenter prospective study in 1, 033 HIV-infected patients. HIV Clin Trials 2002; 3: 279-86.
88. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 2000; 30: 227-28.
89. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2: 105-113.
90. Crixivan (indinavir sulfate) Package Insert. West Point, PA: Merck and Co., Inc; 1999.
91. Viracept (nelfinavir metylase) Package Insert La Jolla, CA: Agouron Pharmaceuticals, Inc; 2001.
92. Agenerase (amprenavir) Package Insert. Research Triangle Park, NC: Glaxo Smith Kline, Inc; 2002.
93. Norvir (ritonavir) Package Insert. North Chicago, IL: Abbott Laboratories; 2001.
94. Fortovase (saquinavir soft gel) Package Insert. Nutley, NY: Roche Laboratories; 2002.
95. Kaletra TM (lopinavir/ritonavir) Package Insert. North Chicago, IL: Abbott Laboratories; 2002.
96. Zucker SD, Qin X, Rooster SD, Yu F, Green RM, Keshavan P, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001; 98: 12671-76.
97. Matsuda J, Gohchi K. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir. Lancet 1997; 350: 364.
98. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283-87.
99. Masur Pb PH, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137:435-478.
100. Vora S, Michon C, Junet C, Balavoine JF, Renold-Moynier C, Yerly S, et al. Switch, from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy coinfected with hepatitis C is not associated with alteration of liver function tests. AIDS 2000; 14: 2795-97.
101. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in nucleus. J Biol Chem 2001; 276: 37514-519.
102. Manfredi R. HIV infection, antiretroviral therapy, and hepatic function. Emerging epidemiological, pathogenetic, and clinical issue, and their consequences on disease management. AIDS 2003; 17:2253-2256.
103. Flexner C. HIV-protease inhibitors. N Engl J Med 1999; 338: 1281-92.
104. Rublein JC, Eron JJ Jr, Butts JD, Raasch RH. Discontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg. Ann Pharmacother 1999; 33: 899-95.
105. Boyle BA. In: Ronald Baker Ed, Toxicities & Side effects. Guide to management of Protease Inhibitor (PI). 2002; 5-25. Available on web site www.HIVandHepatitis.com
106. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42: 3218-3224.
107. Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Disease 2003; 23: 183-93.
108. Poles MA, Dieterich DT, Schawarz ED, Weinshel EH, Lew EA, Lew R, et al. Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquit Immune Defic Syndr Hum Retrovirol 1996; 11: 170-77.
109. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC and the EuroSCAR Study Group. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15: 1843-48.
110. Kessler HA, Johnson J, Follansbee S, Sension MG, Mildvan D, Sepulveda GE, et al. Abacavir expanded access program for adult patients infected with human inummodeficiency virus type 1. Clin Infect Dis 2002; 34: 535-42.
111. Frissen PH, Vries J, Weigel HM, Brinkman K. Severe anaphylactic shock after rechallenge with abacavir without prareding hypersensitivity. AIDS 2001; 15: 289.
112. Boyle BA. In: Ronald Baker Ed, Toxicities. & Side effects. Guide to management of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). 2003; 4-14. Available on web site www.HIVand Hepatitis.com
113. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 2002; 359: 732-32.
114. Brinkmann K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue-reverse-transcriptase inhibitors is a key factor in pathogenesis of antiretroviral therapy related lipodystrophy. Lancet 1999, 354: 1112-115.
115. Gerard Y, Maulin L, Yazdanpanah Y, De La Tribonniere X, Amiel C, Maurage CA, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000; 14: 2723-730.
116. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001; 15: 795-97.
117. Brinkman K. Editorial response; hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis 2000, 31: 167-69.
118. John M, Mallal S. Hyperlactatemia syndromes in people With HIV-infection. Curr Opin Infect Dis 2002; 15: 23-29.
119. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 4, 2002; pag. 16-17.
120. Baubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV-cohort study. Clin Infect Dis 2001; 33: 1931-37.
121. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31: 162-66.
122. Chadock R, Mylonakis E, Shemin D, Runarsdottir V, Yodice P, Renzi R, et al. Survival of a human immunodeficiency patient with nucleoside-induced lactic acidosis - role of haemodialysis treatment. Nephrol Dial Transplant 1999; 14: 2494-486.
123. Schramm C, Wanitschke R, Galle PR. Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. Eur J Anoesthesia 1999; 16: 733-35.
124. Luzzati R, Del Bravo P, Di Perri G, Luzzani A, Concia E. Riboflavin and severe lactic acidosis. Lancet 1999; 353: 901-02.
125. Brinkman K, Vrouenraets S, Kauffmann R, Weigel H, Frissen J. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS 2000; 14: 2801-02.
126. Campos Y, Huertas R, Lorenzo G, Bautista J, Gutierrez E, Aparicio M, et al. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 1993; 43: 884-90.
127. Matthews P, Ford B, Dandurand R, Eidelman DH, O'Connor D, Sherwin A, et al. Coenzyme Q1O with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993; 43: 884-90.
128. Delgado J, Harris M, Tesiorowski A, Montaner JSG. Symptomatic elevations of lactic acid and their response to treatment manipulation in HIV infected individuals - a case series. Clin Infect Dis 2001; 33: 2072-74.
129. Kaslow RA, Blackwelder WC, Ostrow DG, Yerg D, Palenicek J, Coulson AH, Valdiserri RO. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1 positive individuals. A report from the Multicenter AIDS Cohort Study. JAMA 1989; 261: 3424-29.
130. Fabris P, Tositti G, Manfrin V, Giordani MT, Vaglia A, Cattelan AM, Parlotto A. Does alcohol intake affect highly active antiretroviral therapy (HAART) response in HIV-positive patients? J Acquir Immune Defic Syndr 2000; 25: 92-93.
131. Quirishi N, Kreuzeberg C, Lüchters G, Effenberger W, Kupfer B, Sanerbruch T, et al. Effect of antiretroviral therapy on liver related mortality in patients with HIV and hepatitis C coinfection. Lancet 2003; 362: 1708-13.
132. Uberti-Foppa C, De Bona A, Morsica G, Galli M, Gallotta G, Boeri E, Lazzarin A. Pre-treatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 33: 146-52.
133. Soriano, García-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J, et al. Interferon alfa for the treatment of chronic hepatitis C in patients HIV. Clin Infect Dis 1996; 23: 585-91.
134. Puoti M, Bonacini M, Spinetti A, Putzolu V, Govindarajan S, Zaltron S, et al. Liver fibrosis progression is related to CD4 cell depiction in patients coinfected with hepatitis C virus and HIV. J Infect Dis 2001; 183: 134-37.
135. Rockstroh J, Spengler U, Stidhopt T, Ewig S, Theisen A, Hammerstein U, et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996; 91: 2563-68.
136. Landau A, Batisse D, Piketty C, Jian R, Kazatchkine M. Lack of interference between ribavirin and nucleoside analogues in HIV/HCV coinfected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS 2000; 14: 1857-58.
137. Morsica G, De Bona A, Uberti-Foppa C, Sitia G, Finazzi I, Lazzarin A. Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. AIDS 2000; 14: 1656-58.
138. Soriano V, Sulkowsky M, Bergin C, Hatzakis A, Cacoub P, Katlama C, et al. Care of patients with chronic hepatitis C and HIV coinfection: recommendations from the HlV/HCV International Panel. AIDS 2002; 16: 813-28.
139. Kakuda T, Brinkman K. Mitochondrial toxic effects of ribavirin. Lancet 2001; 357: 1802-03.